This new finding demands immediate study
In a study published last month in Vascular Pharmacology, Yuichiro J. Suzuki, a professor at the Department of Pharmacology and Physiology at Georgetown University, and co-workers discovered that the spike protein of SARS-CoV-2 is enough to trigger a response in lab-cultured human endothelial and smooth muscle cells from the lungs’ blood vessels. Yes, just the spike protein, without the whole virion or its genome. — Shin Jie Yong, Neurobiology MSc postgrad in Malaysia
The new mRNA vaccines like Moderna, pFizer-BioNTech, Astra-Zeneca and others are being hailed as the technological breakthroughs that will spawn a whole new litany of effective vaccines. They work by using messenger RNA to cause our cells to manufacture the SARS-CoV-2 (virus that causes COVID-19) spike protein (those little protrusions on the spherical virus image we have all grown familiar with seeing). The thinking is that (a) they are the mechanism the virus uses to gain entry to our cells and (b) on their own, without the whole virus, they are harmless.
This study cited in the quote above claims its results show that the spike protein alone can cause the same thickening of circulatory system walls that causes multiple health issues in COVID patients:
…the SARS-CoV-2 spike protein alone without the rest of the viral components is sufficient to elicit cell signaling in lung vascular cells… Consistent with the activation of cell growth signaling in lung vascular cells by the SARS-CoV-2 spike protein, pulmonary vascular walls were found to be thickened in COVID-19 patients. Thus, SARS-CoV-2 spike protein-mediated cell growth signaling may participate in adverse cardiovascular/pulmonary outcomes…
If verified by additional studies, this helps explain the varied presentations and pathologies of the disease, since the circulatory system permeates the entire body — long suspected, since the ACE2 receptor is a primary target (prevalent in endothelial tissue). But previously, other receptors were not known to be vulnerable. It also means that replication not the only route by which this insidious virus compromises our bodies. The upside is that, as Suzuki goes on to say, effective therapies may be devised based on this mechanism.
For the millions who have already been vaccinated, this may be alarming news. It may be a very good idea to monitor closely for any signs of vascular issues — and make sure these are reported along with the fact that they have received the vaccinations. Currently there are no long-term studies on the side effects of the vaccines. For those (like me) who have received only the first dose of one of the two-dose regimens (Moderna, Pfizer-BioNTech, Astra-Zeneca), it may be advisable to simply leave it there. A new UK study indicates:
In a report submitted to the FDA, researchers discussed vaccine effectiveness in clinical trial participants who’d only gotten one dose of the vaccine.
A vaccine effectiveness of 50.8 percent was found up to 14 days after the first dose. Vaccine effectiveness was 92.1 percent beyond the first 14 days.”
Yong’s article ends with a note of moderation, stating:
…judging from the safety data of the mRNA vaccines clinical trials, we can be assured that the vaccine-induced spike protein production will not cause any major health issues. Perhaps the spike proteins are being made in the right quantity to trigger useful immune responses, and not too much to affect the blood vessels.
And it is possible that we are lucky enough for that to be true. But the bottom line is that this is new information, not available during the development of the vaccines, and if it is true then it’s more down to pure luck than anything else. But the possibility demands immediate attention to determine whether or not that is indeed the case. If it isn’t, we may well start to see an increase in vascular issues that initially are not connected to the vaccines until it’s too late for too many.
mRNA vaccines - a new era in vaccinology
mRNA vaccines represent a promising alternative to conventional vaccine approaches, but their application has been…
Why are mRNA vaccines so exciting? - Harvard Health Blog
The vaccines from Moderna and Pfizer that could soon be available to treat COVID-19 are mRNA vaccines, which have never…
The Viral Fragment Theory of Covid-19 Vascular Complications
SARS-CoV-2 replication alone may not explain Covid-19.
How SARS-CoV-2 proteins affect vascular functionality
As the coronavirus disease (COVID-19) continues to spread, it is speculated that it is also a vascular disease. The…
COVID-19 and vascular disease
An increasing appreciation of the role of endothelial cells in COVID-19 pathogenesis has prompted research into…